Brief: Allovir And Kalaris Therapeutics Announce Merger To Form Company Focused On Retinal Diseases

Kalaris Therapeutics

08/11/2024 11:06

Nov 8 (Reuters) - Allovir Inc  ALVR.O :
    * ALLOVIR AND KALARIS THERAPEUTICS ANNOUNCE AGREEMENT FOR
TRANSFORMATIONAL MERGER TO CREATE COMPANY FOCUSED ON DISEASES OF
THE RETINA
    * ALLOVIR INC - TO ACQUIRE 100% OF KALARIS EQUITY INTEREST
    * ALLOVIR INC - STOCKHOLDERS TO OWN 25.05% OF COMBINED
COMPANY
POST-MERGER
    * ALLOVIR INC - COMBINED COMPANY TO BE LED BY KALARIS CEO
ANDREW
OXTOBY
    * ALLOVIR INC - COMBINED COMPANY TO OPERATE AS KALARIS
THERAPEUTICS, INC. AND TRADE AS KLRS
    * ALLOVIR INC - TH103 PHASE 1 CLINICAL TRIAL DATA EXPECTED
IN Q3
2025

Source text:  ID:nGNX7XVdWQ 
Further company coverage:  ALVR.O 

 ((Reuters.Briefs@thomsonreuters.com;))